Literature DB >> 24953516

New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension.

Philipp Schwabl1, Simona Bota, Petra Salzl, Mattias Mandorfer, Berit A Payer, Arnulf Ferlitsch, Judith Stift, Friedrich Wrba, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger.   

Abstract

BACKGROUND & AIMS: Transient elastography (TE) can non-invasively diagnose cirrhosis and portal hypertension (PHT). New TE reliability criteria suggest classifying measurements as very reliable (IQR/M < 0.1), reliable (IQR<0.3 or >0.3, if TE < 7.1 kPa) and poorly reliable (IQR/M > 0.3, if TE > 7.1 kPa). Compare traditional (reliable: success rate >60% + IQR/M ≤ 0.30) and new TE quality criteria (accurate: very reliable + reliable) regarding their diagnostic accuracy for cirrhosis and PHT and to identify potential confounders (age, aetiology, necroinflammatory activity, steatosis, siderosis, cholestasis, aminotransferases) of TE performance.
METHODS: Patients undergoing simultaneous measurements of TE, portal pressure (hepatic venous pressure gradient, HVPG) and liver biopsy were analysed.
RESULTS: Among 226 patients (48.7 ± 13.1 years, 74.7% male, 75.7% viral aetiology, 57% F3/F4), traditional TE quality criteria identified 71.6% reliable measurements, while new criteria yielded in 83.2% accurate results. Reliable TE values according to both criteria significantly correlated with fibrosis stage (r = 0.648 vs. r = 0.636) and HVPG (r = 0.836 vs. r = 0.846). Diagnostic accuracy for cirrhosis (cut-off >14.5 kPa) was 76.5% (AUC: 0.863) and 75.0% (AUC: 0.852) for traditional and new TE criteria, respectively, while for predicting HVPG ≥ 10 mmHg (>16.1 kPa), the accuracies were 88.9% (AUC: 0.957) and 89.8% (AUC: 0.962). New TE criteria allowed a better discrimination of reliable and non-reliable results for prediction of fibrosis and CSPH. Only aetiology and aminotransferases were independent confounders of the correlation of TE and fibrosis stage, while no confounder affected the correlation of TE and HVPG.
CONCLUSIONS: New reliability criteria for TE measurements increase the number of patients with accurate measurements without affecting diagnostic performance for detecting cirrhosis and portal hypertension. Aetiology of liver disease and aminotransferases should be considered when assessing liver fibrosis by TE.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  fibroscan; liver fibrosis; liver stiffness; portal hypertension; transient elastography

Mesh:

Substances:

Year:  2014        PMID: 24953516     DOI: 10.1111/liv.12623

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  48 in total

1.  Factors Associated with the Quality of Transient Elastography.

Authors:  Eva Juárez-Hernández; Martha Helena Uribe-Ramos; Martha Helena Ramos-Ostos; Angélica Yanine López-Ramírez; Sofía Ornelas-Arroyo; Juan Luis Romero-Flores; Nahúm Méndez-Sánchez; Misael Uribe; Norberto C Chávez-Tapia
Journal:  Dig Dis Sci       Date:  2015-03-11       Impact factor: 3.199

2.  Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis.

Authors:  Jinzhen Song; Zida Ma; Jianbo Huang; Shiyu Liu; Yan Luo; Qiang Lu; Philipp Schwabl; Romanas Zykus; Ashish Kumar; Matthew Kitson
Journal:  Eur Radiol       Date:  2018-06-01       Impact factor: 5.315

3.  Non-invasive Diagnosis of Oesophageal Varices Using Systemic Haemodynamic Measurements by Finometry: Comparison with Other Non-invasive Predictive Scores.

Authors:  Kara Rye; Gerri Mortimore; Andrew Austin; Jan Freeman
Journal:  J Clin Exp Hepatol       Date:  2016-05-13

Review 4.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

5.  Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.

Authors:  Vijendra Kirnake; Anil Arora; Praveen Sharma; Mohan Goyal; Romesh Chawlani; Jay Toshniwal; Ashish Kumar
Journal:  Indian J Gastroenterol       Date:  2018-09-03

Review 6.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

7.  Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.

Authors:  Mattias Mandorfer; Sebastian Steiner; Philipp Schwabl; Berit A Payer; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Thomas Reiberger; Markus Peck-Radosavljevic
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

8.  The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.

Authors:  Rémy Schwarzer; Thomas Reiberger; Mattias Mandorfer; Danijel Kivaranovic; Silvia Hametner; Stephanie Hametner; Rafael Paternostro; Bernhard Scheiner; Jenifer Schneeweiss-Friedl; Michael Trauner; Rainer Schoefl; Andreas Maieron
Journal:  J Gastroenterol       Date:  2019-12-12       Impact factor: 7.527

9.  Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.

Authors:  Georg Semmler; Katharina Wöran; Bernhard Scheiner; Lukas Walter Unger; Rafael Paternostro; Judith Stift; Philipp Schwabl; Theresa Bucsics; David Bauer; Benedikt Simbrunner; Albert Friedrich Stättermayer; Matthias Pinter; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Journal:  United European Gastroenterol J       Date:  2020-01-17       Impact factor: 4.623

Review 10.  Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics.

Authors:  Roxana Şirli; Ioan Sporea; Alina Popescu; Mirela Dănilă
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.